NASDAQ:ORGOOrganogenesis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Organogenesis Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.96 -0.01 (-0.34 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$2.86Now: $2.96▼$3.1950-Day Range$2.86MA: $3.86▼$4.9152-Week Range$2.47Now: $2.96▼$9.14Volume49,779 shsAverage Volume164,832 shsMarket Capitalization$311.87 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOrganogenesis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Organogenesis has a potential upside of 237.8% from its current price of $2.96.Amount of Analyst CoverageOrganogenesis has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesOrganogenesis has received 52 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrganogenesis has received 52 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrganogenesis has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Organogenesis and other stocks. Vote “Outperform” if you believe ORGO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORGO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrganogenesis does not currently pay a dividend.Dividend GrowthOrganogenesis does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organogenesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,408,875.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders70.40% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.86% of the stock of Organogenesis is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Organogenesis are expected to decrease by -16.22% in the coming year, from ($0.37) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organogenesis is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organogenesis is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganogenesis has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.00 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORGO Previous Symbol CUSIPN/A CIKN/A Webhttp://organogenesis.com/ Phone781-575-0775Debt Debt-to-Equity Ratio1.76 Current Ratio2.10 Quick Ratio1.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$260.98 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book5.02Profitability EPS (Most Recent Fiscal Year)($0.42) Net Income$-40,450,000.00 Net Margins-15.50% Return on Equity-126.41% Return on Assets-20.55%Miscellaneous Employees700 Outstanding Shares105,360,000Market Cap$311.87 million Next Earnings Date5/8/2020 (Estimated) OptionableNot Optionable Receive ORGO News and Ratings via Email Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ORGO Rates by TradingView Organogenesis (NASDAQ:ORGO) Frequently Asked Questions How has Organogenesis' stock been impacted by COVID-19 (Coronavirus)? Organogenesis' stock was trading at $2.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ORGO stock has decreased by 0.7% and is now trading at $2.96. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Organogenesis? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Organogenesis. When is Organogenesis' next earnings date? Organogenesis is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Organogenesis. How were Organogenesis' earnings last quarter? Organogenesis Holdings Inc (NASDAQ:ORGO) issued its quarterly earnings results on Monday, March, 9th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.05. The firm had revenue of $74.65 million for the quarter. Organogenesis had a negative return on equity of 126.41% and a negative net margin of 15.50%. View Organogenesis' earnings history. What guidance has Organogenesis issued on next quarter's earnings? Organogenesis updated its FY 2020 After-Hours earnings guidance on Monday, March, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $273-277 million, compared to the consensus revenue estimate of $271.38 million. What price target have analysts set for ORGO? 5 analysts have issued 12 month price targets for Organogenesis' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Organogenesis' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 237.8% from the stock's current price. View analysts' price targets for Organogenesis. Has Organogenesis been receiving favorable news coverage? Media headlines about ORGO stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Organogenesis earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutOrganogenesis. Are investors shorting Organogenesis? Organogenesis saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 169,300 shares, an increase of 43.7% from the February 27th total of 117,800 shares. Based on an average daily trading volume, of 184,300 shares, the short-interest ratio is currently 0.9 days. Approximately 1.6% of the company's stock are sold short. View Organogenesis' Current Options Chain. Who are some of Organogenesis' key competitors? Some companies that are related to Organogenesis include Innoviva (INVA), Ligand Pharmaceuticals (LGND), Karyopharm Therapeutics (KPTI), ZEALAND PHARMA/S (ZEAL), CytoDyn (CYDY), Tricida (TCDA), Heron Therapeutics (HRTX), Zogenix (ZGNX), TG Therapeutics (TGTX), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Y-mAbs Therapeutics (YMAB), NextCure (NXTC), I-Mab (ARQT) and Kiniksa Pharmaceuticals (KNSA). What other stocks do shareholders of Organogenesis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Gilead Sciences (GILD), Opko Health (OPK), Genocea Biosciences (GNCA), OrganiGram (OGI), Ovid Therapeutics (OVID), Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Nokia Oyj (NOK), Outlook Therapeutics (OTLK) and Stitch Fix (SFIX). Who are Organogenesis' key executives? Organogenesis' management team includes the following people: Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)Mr. Patrick Bilbo, Chief Operating Officer (Age 57)Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)Angelyn Lowe, Director of Corp. Communications What is Organogenesis' stock symbol? Organogenesis trades on the NASDAQ under the ticker symbol "ORGO." How do I buy shares of Organogenesis? Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Organogenesis' stock price today? One share of ORGO stock can currently be purchased for approximately $2.96. How big of a company is Organogenesis? Organogenesis has a market capitalization of $311.87 million and generates $260.98 million in revenue each year. The company earns $-40,450,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Organogenesis employs 700 workers across the globe. View additional information about Organogenesis. What is Organogenesis' official website? The official website for Organogenesis is http://organogenesis.com/. How can I contact Organogenesis? Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: What is Depreciation?
